SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-23-214464 from CERENOME, INC. (PSTV)

CERENOME, INC.
Date: Aug. 16, 2023 · CIK: 0001095981 · Accession: 0001193125-23-214464

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-273823

Date
August 16, 2023
Author
Andrew Sims
Form
CORRESP
Company
CERENOME, INC.

Letter

PLUS THERAPEUTICS, INC.

4200 Marathon Blvd.

Suite 200

Austin, TX 78756

August 16, 2023

VIA EDGAR

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Re: Plus Therapeutics, Inc.

Registration Statement on Form S-1 (File No. 333-273823)

Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Plus Therapeutics, Inc., a Delaware corporation, hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-273823) and declare the Registration Statement effective as of Friday, August 18, 2023, at 5:00 p.m., Eastern time, or as soon as practicable thereafter.

Please contact the undersigned at (210) 974-6913, or David Will of Hogan Lovells US LLP at (212) 918-3785 with any questions. Also, please notify Mr. Will when this request for acceleration has been granted.

Very truly yours,
PLUS THERAPEUTICS, INC.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 PLUS THERAPEUTICS, INC.

4200 Marathon Blvd.

 Suite 200

Austin, TX 78756

 August 16, 2023

VIA EDGAR

 Division of Corporation Finance

U.S. Securities and Exchange Commission

 100 F Street, N.E.

Washington, D.C. 20549

Re:
 Plus Therapeutics, Inc.

 Registration Statement on Form S-1 (File No. 333-273823)

 Request for Acceleration of Effective Date

Ladies and Gentlemen:

 Pursuant to Rule 461 of
the General Rules and Regulations under the Securities Act of 1933, as amended, Plus Therapeutics, Inc., a Delaware corporation, hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced
Registration Statement on Form S-1 (File No. 333-273823) and declare the Registration Statement effective as of Friday, August 18, 2023, at 5:00 p.m., Eastern
time, or as soon as practicable thereafter.

 Please contact the undersigned at (210) 974-6913, or
David Will of Hogan Lovells US LLP at (212) 918-3785 with any questions. Also, please notify Mr. Will when this request for acceleration has been granted.

Very truly yours,

PLUS THERAPEUTICS, INC.

By:

 /s/ Andrew Sims

Name: Andrew Sims

Title: Chief Financial Officer

cc:
 David Will, Hogan Lovells US LLP